Pertzye Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The pertzye market research report is one of a series of new reports that provides pertzye market statistics, including the pertzye industry global market size, regional shares, competitors with the pertzye market share, detailed pertzye market segments, market trends, and opportunities, and any further data you may need to thrive in the pertzye industry. This pertzye market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to growing demand for targeted therapies, government initiatives for rare diseases, rising patient population, rising preference for oral therapies, and a shift toward chronic disease management. Major trends in the forecast period include the integration of digital health monitoring for EPI management, advancements in pharmaceutical formulations, technological advancements in drug delivery, the development of biosimilars, and the introduction of new CF drugs targeting genetic mutations.

The rising prevalence of chronic pancreatitis is expected to contribute significantly to the growth of the pertzye market in the coming years. Chronic pancreatitis is a long-term inflammation of the pancreas that results in irreversible damage, digestive problems, and possible complications such as diabetes. Factors such as excessive alcohol consumption, genetic predisposition, autoimmune disorders, and long-term obstruction of pancreatic ducts due to gallstones or tumors are responsible for the increased prevalence of chronic pancreatitis. Pertzye plays a crucial role in managing this condition by providing essential pancreatic enzymes to support digestion and alleviate symptoms of malabsorption in patients with exocrine pancreatic insufficiency. For example, a report in May 2022 from the Australian National University estimated the crude prevalence and incidence rates of pediatric chronic pancreatitis to be 6.8 per 100,000 and 0.98 per 100,000 annually, respectively. As a result, the growing prevalence of chronic pancreatitis is driving the pertzye market's expansion.

The growing emphasis on personalized medicine is also expected to fuel the growth of the pertzye market. Personalized medicine is a healthcare approach tailored to an individual's genetic, environmental, and lifestyle factors, aimed at optimizing treatment and improving outcomes. This shift toward personalized treatments is due to advancements in genomics and biotechnology, which enable more precise therapies based on an individual's genetic profile, leading to improved patient outcomes and fewer side effects. Pertzye, as an enzyme replacement therapy, contributes to this movement by offering tailored treatments for individuals with cystic fibrosis and pancreatic insufficiency, helping to improve digestion and nutrient absorption according to each patient's specific needs. In February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that 16 new personalized treatments were approved by the FDA in 2023 for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the growing emphasis on personalized medicine is driving the pertzye market's growth.

The rise in digestive disorders is another factor expected to drive the growth of the pertzye market. Digestive disorders encompass various conditions that disrupt the normal functioning of the digestive system, including the stomach, intestines, and other related organs. Poor diet, stress, sedentary lifestyles, and environmental toxins are contributing factors to the rise in conditions such as irritable bowel syndrome (IBS), acid reflux, and inflammatory bowel diseases (IBD). Pertzye helps manage digestive disorders by supplying pancreatic enzymes that aid in the breakdown of fats, proteins, and carbohydrates, improving digestion in those with pancreatic insufficiency. For example, according to a report by the IBD Registry, a UK-based non-profit, over 5,300 individuals with Inflammatory Bowel Disease (IBD) were reached by 2023, marking an increase of more than 3,000 members compared to 2022. Consequently, the increasing prevalence of digestive disorders is expected to drive the growth of the pertzye market.

The key company operating in the pertzye market is Digestive Care Inc.

North America was the largest region in the pertzye market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pertzye report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pertzye market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Pertzye is a medication that contains pancrelipase, a blend of lipase, protease, and amylase enzymes. It is used to treat exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce sufficient enzymes for proper digestion. Pertzye is specially formulated with a bicarbonate-buffered enteric coating, which helps ensure the enzymes reach the small intestine, where they assist in digesting fats, proteins, and carbohydrates effectively.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Pertzye is indicated for exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, chronic pancreatitis, pancreatitis surgery, and other related conditions. In cystic fibrosis, EPI occurs when the pancreas is unable to produce enough digestive enzymes, leading to nutrient malabsorption, which is typically treated with pancreatic enzyme replacements such as Pertzye. The medication is available in various formulations, including delayed-release capsules in different strengths, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The pertzye market consists of sales of pancrelipase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.